The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples